Terns Pharmaceuticals, Inc.
TERN
株式のランク
#3571
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
株価
$52.95
最終同期: 2026-05-15
時価総額
$4.77B
変化（1日）
0.00%
変化（1年）
514.27%
国
US
取引 Terns Pharmaceuticals, Inc. (TERN)
カテゴリー
Healthcare
Terns Pharmaceuticals, Inc.（TERN）の発行済株式数
December 2025 時点の発行済株式数 93.17M
Terns Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 93.17M です。December 2023 の終わりには、同社は 71.26M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Terns Pharmaceuticals, Inc.（TERN）の発行済株式数の履歴（2018 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 93.17M | 17.18% |
| 2024 | 79.51M | 11.57% |
| 2023 | 71.26M | 97.76% |
| 2022 | 36.03M | 42.60% |
| 2021 | 25.27M | 0.57% |
| 2020 | 25.13M | 0.11% |
| 2019 | 25.10M | 4.69% |
| 2018 | 23.97M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 172.52% |
US
|
|
| 396.00M | 325.05% |
US
|
|
| 478.91M | 414.04% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -33.25% |
NL
|
